MRKR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRKR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Marker Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was $-0.82 Mil. It means Marker Therapeutics's Accounts Receivable increased by $0.82 Mil from Dec. 2023 to Mar. 2024 .
Marker Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $1.37 Mil. It means Marker Therapeutics's Accounts Receivable declined by $1.37 Mil from Dec. 2022 to Dec. 2023 .
Marker Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Marker Therapeutics's liquidation value for the three months ended in Mar. 2024 was $9.02 Mil.
The historical data trend for Marker Therapeutics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marker Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | 0.05 | 0.06 | 1.00 | -2.40 | 1.37 |
Marker Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 0.32 | 0.34 | 1.66 | -0.95 | -0.82 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marker Therapeutics (NAS:MRKR) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Marker Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Marker Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Marker Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 11.323 | - | 2.304 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 9.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Marker Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Eliot M Lurier | officer: Interim CFO | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Katharine Knobil | director | C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421 |
Frederick Gerald Wasserman | director | 4 NOBADEER DRIVE, PENNINGTON NJ 08534 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Carmen Chang | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
New Enterprise Associates 16, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Paul Edward Walker | director | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Peter L. Hoang | director, officer: CEO and President | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Norman David Eansor | director | 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120 |
Mohamad Makhzoumi | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Ali Behbahani | director | 5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
Florence Anthony A. Jr. | 10 percent owner | 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Forest Baskett | 10 percent owner | |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Juan Vera | director | 2925 RICHMOND AVENUE, SUITE 1274, HOUSTON TX 77098 |
From GuruFocus
By Marketwired • 08-30-2023
By GuruFocus Research GuruFocus Editor • 08-04-2021
By Marketwired • 06-26-2023
By PRNewswire PRNewswire • 07-28-2021
By Marketwired • 07-26-2023
By PRNewswire PRNewswire • 11-10-2021
By Marketwired • 07-10-2023
By GuruFocusNews GuruFocusNews • 02-08-2022
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 08-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.